Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.

脑转移 肺癌
作者
Shengnan Zheng,Huiying Li,Jie Feng,Cheng Jiang,Yongjuan Lin,Yu Xie,Tingting Yu,Xiaoping Qian,Zhenyu Yin
出处
期刊:Anti-Cancer Drugs [Lippincott Williams & Wilkins]
标识
DOI:10.1097/cad.0000000000001222
摘要

Leptomeningeal metastasis (LM) is one of the most serious complications of non-small cell lung cancer (NSCLC) without standard treatment guidelines and is always accompanied by poor prognosis. Identifying the types of gene mutations is essential to improve the outcome, and an increasing number of rare epidermal growth factor receptor (EGFR) mutations are revealed by next-generation sequencing (NGS). Here, we describe a case of a 56-year-old man who was diagnosed with lung adenocarcinoma and received thoracoscopic resection in May 2015. One year later, LM was confirmed by positive cerebrospinal fluid cytology. Given the existence of EGFR exon 19 deletions, erlotinib was implemented and achieved a short response for 10 months. Then the systemic therapy was changed to osimertinib and obtained clinical remission for 25 months. Owing to the resurgence of violent headache, retching and vomiting, NGS of cerebrospinal fluid was performed and two rare EGFR-SEPT14 fusions were found. Osimertinib combined bevacizumab, chemotherapy (carboplatin and abraxane) and dacomitinib were implemented in turn but ineffective. Thus, osimertinib combined intrathecal chemotherapy with pemetrexed were carried out and gained a complete remission of neurologic symptoms, stable lesions and long-term survival without notable side effects. This study presented the first case of NSCLC-LM harboring particular EGFR-SEPT14 fusions, who showed a durable response to osimertinib and intrathecal pemetrexed, providing a potential therapeutic option for NSCLC-LM patients with this particular mutation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liu关闭了liu文献求助
刚刚
刚刚
木可发布了新的文献求助10
1秒前
哈哈哈哈发布了新的文献求助10
1秒前
huangyikun完成签到,获得积分10
2秒前
2秒前
咳咳咳完成签到,获得积分10
2秒前
小二郎应助科研通管家采纳,获得10
3秒前
fd163c应助科研通管家采纳,获得10
3秒前
SYLH应助科研通管家采纳,获得10
3秒前
深情安青应助科研通管家采纳,获得10
3秒前
郑方形发布了新的文献求助20
3秒前
英俊的铭应助科研通管家采纳,获得10
3秒前
SYLH应助科研通管家采纳,获得20
3秒前
酷波er应助科研通管家采纳,获得10
3秒前
Akim应助科研通管家采纳,获得10
3秒前
斯文败类应助科研通管家采纳,获得10
3秒前
MchemG应助科研通管家采纳,获得10
4秒前
英俊的铭应助科研通管家采纳,获得10
4秒前
CAOHOU应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
5秒前
爱撞墙的猫完成签到,获得积分10
5秒前
小马甲应助干雅柏采纳,获得10
5秒前
小晓完成签到,获得积分10
5秒前
becky发布了新的文献求助10
6秒前
jszhoucl发布了新的文献求助10
7秒前
星期八发布了新的文献求助10
7秒前
时有落花至完成签到,获得积分10
7秒前
7秒前
无与伦比发布了新的文献求助30
11秒前
13秒前
一人独钓一江秋完成签到,获得积分10
13秒前
15秒前
16秒前
干雅柏发布了新的文献求助10
18秒前
搜集达人应助俏皮芷蕊采纳,获得10
20秒前
上官若男应助sugar采纳,获得10
21秒前
xxxllllll发布了新的文献求助30
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174